Advanced search
Publication Cover
Scandinavian Journal of Urology and Nephrology Volume 33, 1999 - Issue 203
Submit an article Journal homepage
11
Views
1
CrossRef citations to date
0
Altmetric
Research Article

The Scandinavian Prostatic Cancer Group: A Short Review of its History and Work

Per Olov Hedlund Department of Urology, Karolinska Hospital, S-171 76 Stockholm, Sweden
Pages 53-56 | Published online: 09 Jul 2009

REFERENCES

  • Horder M, Rasmussen F. Acid phosphatases and other tumor markers in the management of prostatic cancer. Scand J Clin Invest 1985; 45 Suppl 179: 1–117.
  • Benson Jr RC, Gill GMG. Estramustine phosphate compared with diethylstilbestrol. Am J Clin Oncol 1986; 9: 341–51.
  • Hedlund PO, Jacob sson H, Vaage S, Hahne B, Sandin T, Kontturi M, et al. Treatment of high-grade, high-stage prostate cancer with estramustine phosphate or diethyl-stilbestrol. Scand J Urol Nephrol 1996; 31: 167–72.
  • Jorgensen T, Tveter KJ—and the members of the SPCG-2 group. Total androgen suppression: experience from the Scandinavian Prostatic Cancer Group Study No. 2 Eur Urol 1993; 24: 466–70.
  • Jorgensen T. Prognostic factors in metastatic prostate cancer: experience based on the SPCG Study No 2: In press.
  • Aro J, Ruutu M, Juusela H, Hansson E, Permi J—and the Finnprost Group. Polyestradiol phosphate (160 mg/ month) or LHRH analog (Buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. Ann Chir et Gyn 1993; 82: 5–8.
  • Henriksson P. Blombäck M, Eriksson A, Stege R, Carlström K. Effect of parenteral oestrogen on the coagulation system in patients with prostatic carcinoma. Br J Urol 1990; 65: 282–5.
  • Lukkarinen O, Kontturi M—and the Finnish Zoladex Multicenter Study Group. Comparison of a long-acting LHRH agonist and polyestradiol phosphate in the treatment of advanced prostatic carcinoma. Scand J Urol Nephrol 1994; 28: 171–8.
  • Mikkola AKK, Ruutu ML, Aro JIN, Rannikko SAS, Salo JO—on behalf of the Finnprost Group. Parenteral polyestradiol phosphate vs orchiectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovas-cular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Br J Urol 1998; 82: 63–8.
  • Hedlund PO, Gustafsson H, Sjögren S. Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt6) or conventional estrogen. Scand J Urol Nephrol 1980; 14 Suppl 55: 103–5.
  • Iversen P. Carcinoma of the prostate. Views and recommendations. Scand J Urol Nephrol 1991; 25 Suppl 139: 1–63.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.